J Rheum Dis.  2021 Apr;28(2):53-54. 10.4078/jrd.2021.28.2.53.

The Baseline Serum IgG4/IgG3 Ratio Might be a Suitable Marker for Predicting Favorable Treatment Response in Patients With Idiopathic Retroperitoneal Fibrosis-associated Hydronephrosis

• Kwok SK

• KMID: 2514114
• DOI: http://doi.org/10.4078/jrd.2021.28.2.53

Reference

1. Vaglio A, Salvarani C, Buzio C. 2006; Retroperitoneal fibrosis. Lancet. 367:241–51. DOI: 10.1016/S0140-6736(06)68035-5. PMID: 16427494.

2. Baker LR, Mallinson WJ, Gregory MC, Menzies EA, Cattell WR, Whitfield HN, et al. 1987; Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol. 60:497–503. DOI: 10.1111/j.1464-410X.1987.tb05028.x. PMID: 3427331.

3. Vaglio A, Maritati F. 2016; Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol. 27:1880–9. DOI: 10.1681/ASN.2015101110. PMID: 26860343. PMCID: PMC4926988.

4. Khosroshahi A, Carruthers MN, Stone JH, Shinagare S, Sainani N, Hasserjian RP, et al. 2013; Rethinking Ormond's disease: "idiopathic" retroperitoneal fibrosis in the era of IgG4- related disease. Medicine (Baltimore). 92:82–91. DOI: 10.1097/MD.0b013e318289610f. PMID: 23429355. PMCID: PMC4553983.

5. Magrey MN, Husni ME, Kushner I, Calabrese LH. 2009; Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum. 61:674–9. DOI: 10.1002/art.24461. PMID: 19404998.

6. Pelkmans LG, Aarnoudse AJ, Hendriksz TR, van Bommel EF. 2012; Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant. 27:2819–25. DOI: 10.1093/ndt/gfr779. PMID: 22273666.

7. Zhao J, Li J, Zhang Z. 2019; Long-term outcomes and predictors of a large cohort of idiopathic retroperitoneal fibrosis patients: a retrospective study. Scand J Rheumatol. 48:239–45. DOI: 10.1080/03009742.2018.1497700. PMID: 30270709.

8. Choi SJ, Oh JS, Hong S, Lee CK, Yoo B, Hong B, et al. 2021; Treatment response to idiopathic retroperitoneal fibrosis-associated hydronephrosis with a focus on IgG4/IgG3 serum concentration ratio. J Rheum Dis. 28:38–44. DOI: 10.4078/jrd.2021.28.1.38.